title: Overview of a quality assurance/quality control compliance program consistent with FDA regulations and policies for somatic cell and gene therapies: a four year experience.
abstract: Somatic cell and gene therapy involve the application of biological technologies to an individual patient through the use of living cells which provide a therapeutic benefit (Aliski, 1991). Various forms of cellular and gene therapies are being developed and evaluated in an increasing number of clinical trials for congenital and acquired disorders. The potential and progress of these therapeutic applications have resulted in an increasing effort by the Food and Drug Administration (FDA) to develop the regulatory framework under which these therapeutic approaches would insure safety and efficacy, the primary mandate of the FDA. Over five years ago Cellcor began to define the parameters, specifications, and conditions relevant to a Quality Assurance/Quality Control (QA/QC) program that has evolved to insure safety and maximize the efficacy of applications of the company's ex vivo technology, autolymphocyte therapy. Autolymphocyte therapy is an outpatient form of somatic cell immunotherapy based upon the infusion of T cells that have been activated ex vivo using a combination of previously generated autologous cytokines and an anti-CD3 monoclonal antibody. We have been able to demonstrate the feasibility for the safe, controlled, and consistent preparation and delivery of a cellular therapy by application of relevant GMP regulations. This presentation reviews aspects of this program and chronicles our experience which at present amounts to over 4400 in fusions for over 700 patients. This program provides a high degree of assurance that a cellular therapy program can be carried out in a multisite mode involving hundreds of patients through the strict adherence to cGMP as set forth in existing regulations.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Quality Control, Cellcor, Inc., Newton, MA 02159.
authors.forename: G C
authors.initials: GC
authors.lastname: du Moulin
authors.forename: Z
authors.initials: Z
authors.lastname: Pitkin
authors.forename: Y J
authors.initials: YJ
authors.lastname: Shen
authors.forename: E
authors.initials: E
authors.lastname: Conti
authors.forename: J K
authors.initials: JK
authors.lastname: Stewart
authors.forename: C
authors.initials: C
authors.lastname: Charles
authors.forename: D
authors.initials: D
authors.lastname: Hamilton
mesh_terms: D017690:Cell Transplantation / Q000331:legislation & jurisprudence / Q000592:standards*; D046508:Culture Techniques / Q000592:standards*; D015316:Genetic Therapy / Q000331:legislation & jurisprudence / Q000592:standards*; D006291:Health Policy / Q000331:legislation & jurisprudence; D006801:Humans; D017710:Lymphocyte Transfusion / Q000592:standards*; D011785:Quality Assurance, Health Care; D011786:Quality Control; D013601:T-Lymphocytes; D014481:United States; D014486:United States Food and Drug Administration